Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics
AKRO Price/Volume Stats
| Current price | $20.51 | 52-week high | $58.38 |
| Prev. close | $21.60 | 52-week low | $11.25 |
| Day low | $20.42 | Volume | 760,800 |
| Day high | $21.46 | Avg. volume | 1,281,893 |
| 50-day MA | $24.56 | Dividend yield | N/A |
| 200-day MA | $29.56 | Market Cap | 1.15B |
AKRO Stock Price Chart Interactive Chart >
Akero Therapeutics, Inc. (AKRO) Company Bio
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Latest AKRO News From Around the Web
Below are the latest news stories about AKERO THERAPEUTICS INC that investors may wish to consider to help them evaluate AKRO as an investment opportunity.
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY ProgramWeek 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to Review Phase 3 Study and Regulatory Path for Treatment of NASH/MASH Patients with Compensated Cirrhosis (F4) SOUTH SAN FRANCISCO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious me |
Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ...In a notable insider trading event, President and CEO Andrew Cheng of Akero Therapeutics Inc (NASDAQ:AKRO) sold 26,978 shares of the company on December 11, 2023. |
12 Most Promising Stocks to Buy According to Hedge FundsIn this article, we will take a look at the 12 most promising stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Promising Stocks to Buy According to Hedge Funds. Analysts and financial institutions are starting to release their 2024 market outlook reports and predictions and you […] |
Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial ResultsAdvances in NASH Treatment Candidate Efruxifermin (EFX) with Phase 3 Trials on the Horizon |
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates. “We continue to be encouraged b |
AKRO Price Returns
| 1-mo | -18.58% |
| 3-mo | -6.39% |
| 6-mo | 64.34% |
| 1-year | -52.00% |
| 3-year | -26.41% |
| 5-year | N/A |
| YTD | -12.16% |
| 2023 | -57.39% |
| 2022 | 159.10% |
| 2021 | -18.02% |
| 2020 | 16.24% |
| 2019 | N/A |
Loading social stream, please wait...